Drugs / CAT-2003
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01725594 | Nov 2012 → May 2013 | hyperlipidemia | Catabasis Pharmaceuticals | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02098278 | Mar 2014 → Apr 2015 | familial lipoprotein lipase deficiency, hypertriglyceridemia 1 | Catabasis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01968720 | Oct 2013 → Apr 2014 | hyperlipidemia, hypertriglyceridemia | Catabasis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01912560 | Jul → Dec 2013 | hyperlipidemia, hypertriglyceridemia | Catabasis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAT-2003 | “A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003” NCT01725594 ↗ |